Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a biotechnology company focused on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. We have two product candidates that are currently in clinical development, and one in pre-clinical evaluation. iSONEP iSONEP™ is the ocular formulation of sonepcizumab, a humanized monoclonal antibody (“mAb”) against sphingosine-1-phosphate (“S1P”). Sphingomab™ is the original mouse version of this monoclonal antibody. iSONEP is administered by intravitreal injection, and has demonstrated multiple mechanisms of action in ocular models of disease, including anti-angiogenesis, anti-inflammatory, anti-fibrotic and anti-vascular permeability. ... More ...
Analyst Info |
|
| Annual EPS Est: | $ |
| Quarterly EPS Est: | |
| PEG Ratio: | N/A |
|
Mean Recommendation: View Summary / View All |
0 |
Data is provided by Zacks Investment Research
